Company News: GlaxoSmithKline

Share this article:
GlaxoSmithKline dedicated a new $300,000 production facility at its Nashik site in India to the manufacture of albendazole as part of the World Health Organization's anti-lymphatic filariasis program. The plant will produce 300 million treatments of the drug per year. Lymphatic filariasis, or elephantitis, is a tropical parasitic infection spread by mosquitoes and causing grotesque, painful swelling of the limbs, breasts and genitals. An estimated 120 million people in 83 countries are currently infected.
Share this article:

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.